1
Home
Companies

Arvinas

#7001

Rank

$443.06M

Marketcap

US United States

Country

Arvinas
Leadership team

Dr. John G. Houston Ph.D. (CEO, Pres & Director)

Mr. Sean A. Cassidy CPA, CPA, M.B.A. (CFO & Treasurer)

Dr. Ian Taylor Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Number of Employees
100 - 500
Headquarters
New Haven, Connecticut, United States
Established
2013
Company Registration
SEC CIK number: 0001655759
Revenue
100M - 500M
Traded as
ARVN
Social Media
URL
https://www.arvinas.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
History

Arvinas was founded in 2013 by Princeton University professor Craig Crews, who introduced the concept of protein degradation as a novel approach to drug discovery. In that same year, the first round of venture capital funding was secured and work began on the revolutionary PROTAC technology. In 2017, Arvinas entered into a collaboration with Pfizer to develop gene-editing drugs. In 2020, Arvinas went public on the Nasdaq and raised more than $425 million.

Mission
Arvinas’ mission is to save lives by changing the way disease is treated through protein degradation therapeutics.
Vision
Arvinas’ vision is to become a leader in protein degradation therapeutics and to provide revolutionary treatments for cancer and other diseases.
Key Team

Dr. Ronald A. Peck (Chief Medical Officer)

Mr. Jeff Boyle (VP of Investor Relations)

Dr. John A. Grosso Ph.D. (Sr. VP of R&D Technical Operations)

Ms. Angela M. Cacace Ph.D. (Sr. VP of Neuroscience & Platform Biology)

Dr. Randy Teel Ph.D. (Sr. VP of Corp. & Bus. Devel.)

Mr. Matthew Batters J.D. (Gen. Counsel & Corp. Sec.)

Mr. Steve Weiss (Sr. VP & Chief HR Officer)

Recognition and Awards
Arvinas has received numerous awards for its innovative technologies, including the 2019 Forbes Breakthrough Award and the MIT Technology Review Magazine’s Top 10 Emerging Technologies of 2020. In 2020, Arvinas was named a Top Ten Fintech Disruptor by CB Insights.
References

https://in.investing.com/equities/arvinas-holding

https://finance.yahoo.com/quote/ARVN/profile?p=ARVN

https://www.crunchbase.com/organization/arvinas

https://sec.report/CIK/0001655759

https://companiesmarketcap.com/

https://www.arvinas.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Arvinas
Leadership team

Dr. John G. Houston Ph.D. (CEO, Pres & Director)

Mr. Sean A. Cassidy CPA, CPA, M.B.A. (CFO & Treasurer)

Dr. Ian Taylor Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Number of Employees
100 - 500
Headquarters
New Haven, Connecticut, United States
Established
2013
Company Registration
SEC CIK number: 0001655759
Revenue
100M - 500M
Traded as
ARVN
Social Media
URL
https://www.arvinas.com